BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16619516)

  • 1. Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs.
    Natsume T; Watanabe J; Horiuchi T; Kobayashi M
    Anticancer Res; 2006; 26(2A):1145-51. PubMed ID: 16619516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.
    Kobayashi M; Natsume T; Tamaoki S; Watanabe J; Asano H; Mikami T; Miyasaka K; Miyazaki K; Gondo M; Sakakibara K; Tsukagoshi S
    Jpn J Cancer Res; 1997 Mar; 88(3):316-27. PubMed ID: 9140117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo.
    Natsume T; Watanabe J; Koh Y; Fujio N; Ohe Y; Horiuchi T; Saijo N; Nishio K; Kobayashi M
    Cancer Sci; 2003 Sep; 94(9):826-33. PubMed ID: 12967483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antitumor activity of combination treatment combining gemcitabine with topotecin against human lung cancer xenografted in nude mice].
    Fujita F; Koike M; Fujita M
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):577-84. PubMed ID: 11977542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current perspectives of new agents in lung cancer].
    Fukuoka M
    Nihon Rinsho; 2000 May; 58(5):1103-10. PubMed ID: 10824557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.
    Green MR
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):17-21. PubMed ID: 12170447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
    Rigas JR
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):15-20. PubMed ID: 11441410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenging the platinum combinations in the chemotherapy of NSCLC.
    Douillard JY; Eckardt J; Scagliotti GV
    Lung Cancer; 2002 Dec; 38 Suppl 4():21-8. PubMed ID: 12480191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
    Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K
    Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Developed new agents for lung cancer].
    Kato Y; Saijo N
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):218-23. PubMed ID: 11904983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
    Georgoulias V; Kouroussis C; Agelidou A; Boukovinas I; Palamidas P; Stavrinidis E; Polyzos A; Syrigos K; Veslemes M; Toubis M; Ardavanis A; Tselepatiotis E; Vlachonikolis I;
    Br J Cancer; 2004 Aug; 91(3):482-8. PubMed ID: 15238986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Outpatient chemotherapy for lung cancer].
    Yoneda S
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):533-7. PubMed ID: 17431337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy for advanced non-small cell lung cancer].
    Ueoka H
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):770-6. PubMed ID: 15984514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy in metastatic non-small-cell lung cancer.
    Sandler A
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):15-27. PubMed ID: 10981287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine-based combination treatment of pancreatic cancer.
    Heinemann V
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):25-35. PubMed ID: 11894005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
    Mavroudis D
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S42-5. PubMed ID: 11924243
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro simulation study of individualized chemotherapy in lung cancer.
    Li C; Gemma A; Minegishi Y; Matsuda K; Seike Y; Noro R; Shionoya A; Kawakami A; Ogawa N; Kudoh S
    J Nippon Med Sch; 2007 Jun; 74(3):217-22. PubMed ID: 17625370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoradiation in locally advanced non-small cell lung cancer.
    Bonomi P; Shirazi W
    Cancer Treat Res; 2001; 105():171-88. PubMed ID: 11224987
    [No Abstract]   [Full Text] [Related]  

  • 20. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
    Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.